Delivery Order SPE2DB22D3501-SPE2DB25FWN75
- Not listed
- The Defense Logistics Agency awarded a $12,962.95 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of SKYRIZI 150 mg/ml pen injections. This is a firm fixed-price contract with an ultimate completion date of July 28, 2025, and was competitively awarded with no set-aside designation. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive $999,999,999.00...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $42,722.77 by the Defense Logistics Agency on July 21, 2025, for the supply of SKYRIZI 150 mg/ml pen milliliter pharmaceutical product. The contract is designated as firm fixed price with no set-aside provision and carries an ultimate completion date of July 22, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued...
- The Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order on July 24, 2025, for SKYRIZI 150 mg/mL pens valued at $17,794.40 under a firm fixed price arrangement. This non-set-aside award is scheduled for completion by July 25, 2025, with delivery performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal...
- The Defense Logistics Agency awarded a $34,799.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for SKYRIZI 150 MG/ML in pen milliliter formulation, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a pharmaceutical supply delivery executed through competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor within the federal medical supply chain,...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen, a pharmaceutical product used in dermatological treatment. This firm fixed-price delivery order, awarded on July 23, 2025, is classified as non-set-aside and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 24, 2025. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $28,396.90 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen/ml, a pharmaceutical product. The contract, awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, utilizes firm fixed price pricing and carries no set-aside designation, indicating competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 23, 2025, for SKYRIZI 150 mg/ml pen medication. This firm fixed-price contract, valued at $35,400.44, represents a non-competitive set-aside delivery order with an ultimate completion date of July 24, 2025. The award leverages AmerisourceBergen's established position within the federal pharmaceutical supply...
- The Defense Logistics Agency awarded a $21,311.56 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen, a pharmaceutical product for dermatological treatment. This competitively awarded, firm fixed-price delivery order was issued on July 22, 2025, with an ultimate completion date of July 23, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $37,510.45 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/mL, a pharmaceutical product. This firm fixed price contract, issued on July 21, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 comprehensive pharmaceutical supply agreement running through December 2026. The contract was competitively awarded...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,797.51 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWN75Delivery Order
The Defense Logistics Agency awarded a $50,801.12 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of SKYRIZI 150 mg/mL pen/mL, a pharmaceutical product used to treat inflammatory conditions. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by July 24, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems globally. The company's extensive federal contract portfolio with the Defense Logistics Agency demonstrates its established capability to meet competitive procurement requirements and deliver critical pharmaceutical products across multiple therapeutic domains to the Defense Health Agency and related government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $50.8k | 7/23/25 |